We provide product-by-product Rx sales analysis of companiesunder our watch. The Rx sales data are based on a sample of690 hospitals.    Products that registered fast growth in July: 3SBio's SEPO +82%, CSPC's Jinyouli+100%, United Labs' Uslin +25%, and Hengrui's Aitan (apatinib) +119%. UnitedLabs' Uslen (insulin glargine) has launched in May. It has won tenders in fiveprovinces (Fujian, Chongqing, Heilongjiang, Henan, Guangdong), and so far Rxsales of Uslen were registered in Fujian and Chongqing.    US sales: Hengrui's cyclophosphamide injection sales were US$98mn in Jan-Julsold through Sandoz, -1% YoY (IMS US). Hengrui's sevoflurane, now in its sixthmonth after launch, also sold through Sandoz. So far, as the third genericentrant, it has less than 1% share of category sales. We keep our eyes open forthe launch of the recently approved cisatracurium in the US for Hengrui.    See inside for prescription growth of all key products.

声明：如本站内容不慎侵犯了您的权益，请联系邮箱：wangshiyuan@epins.cn 我们将迅速删除。